Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial

Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous non-small-cell lung cancer: results from a randomized, double-blind, phase 3 trial (ORIENT-12)

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.04.011 ◽

2021 ◽

Author(s):

Caicun Zhou ◽

Lin Wu ◽

Yun Fan ◽

Zhehai Wang ◽

Lianke Liu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

First Line Treatment with Erlotinib Plus Bevacizumab or with Erlotinib Alone in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations (NEJ026): An Open-Label, Randomized, Multicenter, Phase 3 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3271416 ◽

2018 ◽

Author(s):

Haruhiro Saito ◽

Tatsuro Fukuhara ◽

Naoki Furuya ◽

Kana Watanabe ◽

Shunichi Sugawara ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Multicenter Phase ◽

Crizotinib vs platinum‐based chemotherapy as first‐line treatment for advanced non‐small cell lung cancer with different ROS1 fusion variants

Cancer Medicine ◽

10.1002/cam4.2984 ◽

2020 ◽

Vol 9 (10) ◽

pp. 3328-3336 ◽

Cited By ~ 3

Author(s):

Haiyan Xu ◽

Quan Zhang ◽

Li Liang ◽

Junling Li ◽

Zhefeng Liu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC

Annals of Oncology ◽

10.1093/annonc/mdy511.005 ◽

2018 ◽

Vol 29 ◽

pp. x40-x41 ◽

Cited By ~ 41

Author(s):

N.A. Rizvi ◽

B. Chul Cho ◽

N. Reinmuth ◽

K.H. Lee ◽

M.-J. Ahn ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

FAST-ACT: A phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.8031 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 8031-8031 ◽

Cited By ~ 12

Author(s):

J. S. Lee ◽

J. Ignacio ◽

C. Yu ◽

C. Zhou ◽

Y. Wu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Small Cell ◽

Line Treatment ◽

Double Blind Trial ◽

Small Cell Lung ◽

First Line ◽

Double Blind ◽

A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1097/jto.0b013e318226b5fa ◽

2011 ◽

Vol 6 (11) ◽

pp. 1907-1914 ◽

Cited By ~ 48

Author(s):

José Rodrigues-Pereira ◽

Joo-Hang Kim ◽

Manuel Magallanes ◽

Dae Ho Lee ◽

Jie Wang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Phase 3 ◽

PCN82 Cost-Effectiveness Analysis of Erlotinib Versus Platinum Based Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer EGFR Activating Mutations

Value in Health ◽

10.1016/j.jval.2012.08.2122 ◽

2012 ◽

Vol 15 (7) ◽

pp. A424

Author(s):

P. Garrido ◽

G. López-Vivanco ◽

R. Rosell ◽

B. Espinós ◽

A. Castro-Gomez

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Activating Mutations ◽

Effectiveness Analysis ◽

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(11)70184-x ◽

2011 ◽

Vol 12 (8) ◽

pp. 735-742 ◽

Cited By ~ 2256

Author(s):

Caicun Zhou ◽

Yi-Long Wu ◽

Gongyan Chen ◽

Jifeng Feng ◽

Xiao-Qing Liu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Egfr Mutation ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

The efficacy and safety of bevacizumab in addition to platinum‑based chemotherapy for the first‑line treatment of patients with advanced nonsquamous non‑small‑cell lung cancer: Final results of AVALANCHE, an observational cohort study

Oncology Letters ◽

10.3892/ol.2018.9766 ◽

2018 ◽

Cited By ~ 1

Author(s):

Edina Tolnay ◽

�ron Ghimessy ◽

Erzs�bet Juh�sz ◽

Zsuzsanna Sztancsik ◽

Gy�rgy Losonczy ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Observational Cohort Study ◽

Line Treatment ◽

Efficacy And Safety ◽

Small Cell Lung ◽

First Line ◽

Observational Cohort ◽

Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants

Annals of Oncology ◽

10.1093/annonc/mdz260.075 ◽

2019 ◽

Vol 30 ◽

pp. v640

Author(s):

H. Xu ◽

Q. Zhang ◽

L. Liang ◽

J. Li ◽

Z. Liu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽